New Medication Effective Against Chronic Hives

Sunday, 06 Oct 2013 10:10 AM

 

Share:
  Comment  |
   Contact Us  |
  Print  
|  A   A  
  Copy Shortlink
Swiss drugmaker Novartis said on Saturday its drug omalizumab was almost doubly effective in improving quality of life for patients with a severe form of hives, compared with a placebo, according to a late-stage study.

The third and final late-stage study of omalizumab for treating the skin disease chronic spontaneous urticaria (CSU) found the drug was nearly twice as effective versus a placebo in improving life quality within 12 weeks of treatment, while also significantly reducing itch and hives caused by the condition.

Novartis said it had filed applications for the approval of omalizumab for treating patients with CSU to U.S. and European Union health authorities in the third quarter.
 
Omalizumab, which is also known as Xolair, is already approved for treating severe asthma.

© 2014 Thomson/Reuters. All rights reserved.

Share:
  Comment  |
   Contact Us  |
  Print  
  Copy Shortlink
Around the Web
Join the Newsmax Community
Please review Community Guidelines before posting a comment.
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
 
Email:
Country
Zip Code:
Privacy: We never share your email.
 
Hot Topics
Follow Newsmax
Like us
on Facebook
Follow us
on Twitter
Add us
on Google Plus
Around the Web
Top Stories
You May Also Like

'Ebola Mice' Developed to Fast-Track Vaccine Research

Friday, 31 Oct 2014 15:18 PM

Researchers have developed the first genetic strain of mice that can be infected with Ebola and used to test new drugs a . . .

Is Your Drinking Water Wrecking Your Heart?

Friday, 31 Oct 2014 15:15 PM

Arsenic in drinking water, even at trace levels, may increase the risk of heart disease, researchers have found. . . .

Daylight Saving Dangerous for Diabetics

Friday, 31 Oct 2014 15:11 PM

Forgetting to turn back the clock as part of the annual ritual of daylight savings time is especially important for diab . . .

Most Commented

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

 
NEWSMAX.COM
America's News Page
©  Newsmax Media, Inc.
All Rights Reserved